The program Congress established to speed commercial development of vaccines and treatments to counter a potential bioterror attack is moving too slowly, biotechnology industry officials told lawmakers Thursday.
The program Congress established to speed commercial development of vaccines and treatments to counter a potential bioterror attack is moving too slowly, biotechnology industry officials told lawmakers Thursday.